Doxepin vs Zolpidem for Sleep-Maintenance Insomnia

What doxepin (Silenor) is, and why the dose matters

Doxepin is a tricyclic compound that has been prescribed at 75-300 mg for depression since the 1960s. The branded formulation Silenor uses a dose 10 to 100 times lower, 3 mg or 6 mg. At that low a dose, the antidepressant, anticholinergic, and adrenergic effects that define doxepin as a tricyclic become much less prominent, while its high affinity for histamine H1 receptors remains active. The FDA approved Silenor in 2010 specifically for sleep-maintenance insomnia in adults, based on this dose-dependent shift in pharmacology, and the current prescribing information is available directly from the FDA (Silenor label, accessdata.fda.gov).

Histamine, released by neurons in the hypothalamus, is a wake-promoting signal. Blocking H1 receptors at low doses is thought to reduce arousal near the end of the sleep period, which is the mechanistic reason doxepin is studied for staying-asleep problems rather than falling-asleep problems. This is a plausible and label-consistent explanation, not something this article can independently confirm at the level of neuronal circuitry; readers who want the underlying trial data should consult the FDA label and the primary trial literature rather than secondary summaries, including this one.

Doxepin (Silenor) is FDA-approved at 3 mg or 6 mg for adults with sleep-maintenance insomnia, doses low enough that the drug acts primarily as a histamine H1 antagonist rather than as a classic tricyclic antidepressant. This is a mechanistically distinct approach from GABA-A-acting hypnotics (zolpidem, eszopiclone, zaleplon) and from melatonin, which addresses circadian timing rather than nighttime arousal. As of 2025, doxepin has not been compared with these other agents in a published head-to-head randomized trial, so claims that it is "better" or "safer" than a specific competitor should be treated as unproven rather than established.

How doxepin's mechanism differs from z-drugs and benzodiazepines

Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) act on GABA-A receptors, the same receptor family targeted by benzodiazepines. Positive modulation of GABA-A receptors produces sedation quickly, and this class is associated in the literature with reduced slow-wave sleep, a risk of rebound insomnia after stopping, and physical dependence with prolonged use.

Doxepin at 3-6 mg works through a separate pathway, selective histamine H1 antagonism, which is the basis for several practical distinctions:

• Scheduling. Doxepin at any dose carries no DEA controlled-substance schedule. Zolpidem, eszopiclone, and zaleplon are Schedule IV. This matters for patients with a personal or family history of substance use disorder, though the decision to prescribe any sedating medication in that population should still involve individualized clinical judgment.
• Sleep architecture and rebound insomnia. The FDA approval package and subsequent literature describe doxepin at sleep doses as not producing the rebound-insomnia pattern seen with some GABA-A hypnotics on discontinuation. This is a reasonably well-supported distinction. A 2024 narrative comparison of melatonin, trazodone, and doxepin for sleep problems in psychiatric populations discusses these mechanistic and tolerability differences, though it is a narrative review rather than a head-to-head trial and should be read as background, not proof of superiority (Addressing Sleep Disorders in Psychiatry: Comparing Melatonin, Trazodone, and Doxepin, 2024).
• Onset speed. Zolpidem and zaleplon are absorbed quickly and are suited to sleep-onset problems (trouble falling asleep). Doxepin's peak effect at sleep doses is slower, which is consistent with its indication for sleep-maintenance rather than sleep-onset insomnia.

Dosing and label requirements

According to the FDA-approved label, the sleep-dose range for doxepin is 3 mg or 6 mg, taken once daily within about 30 minutes of bedtime, with at least 7-8 hours available for sleep before the planned wake time. The label also instructs against taking the dose immediately after a high-fat meal, since food delays absorption. Readers should consult the current label directly for exact wording and any post-2010 label updates, since prescribing information can be revised.

There is no FDA-approved dose above 6 mg for insomnia. Prescribing doxepin at antidepressant-range doses (75-300 mg) for sleep is off-label and substantially increases anticholinergic and cardiovascular risk; this is a meaningfully different risk category from the approved sleep dose and should not be conflated with it.

Generic doxepin tablets at 3 mg and 6 mg are available and are typically the same active drug as Silenor at a lower price point, though exact pricing and insurance coverage change over time and should be confirmed with a pharmacy at the time of filling a prescription.

Side effects, contraindications, and interactions

At sleep doses, doxepin's side-effect profile is narrower than at antidepressant doses, though not absent. Commonly reported effects in the trials supporting FDA approval include somnolence, nausea, and upper respiratory tract infection; this article does not restate exact incidence percentages because the specific figures in the original draft could not be verified against a confirmed source and an unverified precise number is worse than an honest range. Readers who want exact adverse-event rates should pull them directly from the current FDA label.

Absolute contraindications per the FDA label include untreated narrow-angle glaucoma, significant urinary retention, and concurrent use of monoamine oxidase inhibitors (MAOIs) or use within about two weeks of stopping one. Doxepin is metabolized through CYP2D6 and CYP1A2, so strong CYP2D6 inhibitors (for example, some SSRIs) and cimetidine can raise doxepin levels; combining doxepin with alcohol, benzodiazepines, opioids, or other CNS depressants adds sedation risk. Anyone on multiple interacting medications should have this reviewed by the prescriber rather than relying on a general list like this one.

At higher, antidepressant-range doses, doxepin is associated with QTc prolongation and orthostatic hypotension. Whether these cardiac effects occur at 3-6 mg in patients who already have cardiac disease is not something this article can confirm with the sources available; a cautious approach is to disclose cardiac history to the prescriber and treat this as an open question rather than a settled reassurance.

Doxepin vs. melatonin: different problems, different evidence

Melatonin is a hormone that signals circadian timing; over-the-counter melatonin supplements are not FDA-regulated for efficacy or purity the way prescription drugs are. Melatonin is generally considered most useful for circadian-phase problems such as jet lag, delayed sleep phase disorder, and shift-work-related sleep timing issues, rather than for maintaining sleep once asleep.

Doxepin at 3-6 mg is FDA-approved specifically for sleep-maintenance insomnia, meaning falling asleep normally but waking too early or too often. A practical distinction some clinicians use: if the complaint is "I can't fall asleep," a circadian approach (melatonin, or a prescription melatonin-receptor agonist) is more mechanistically aligned. If the complaint is "I fall asleep fine but wake at 3 or 4 a.m.," doxepin's approved indication matches that complaint more directly. This is a reasonable clinical heuristic based on each drug's mechanism and label, not a claim that either drug has been proven superior to the other in a trial that enrolled both.

Doxepin vs. zolpidem, eszopiclone, and zaleplon

Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are all FDA-approved, Schedule IV, GABA-A-acting hypnotics. In January 2013, the FDA required lower recommended zolpidem doses after data showed that some patients, especially women, had next-morning blood levels high enough to impair driving, according to an FDA drug safety communication from that time. That same communication is a useful reminder that "non-controlled" or "low next-day impairment" claims about any hypnotic, including doxepin, deserve the same scrutiny rather than being taken on faith from a single trial.

Zolpidem's risks are not limited to driving. A 2024 study examining zolpidem use in patients with chronic obstructive pulmonary disease reported safety concerns specific to that population, a reminder that hypnotic choice should account for comorbid respiratory disease, not just insomnia type (Risks of Zolpidem among Patients with Chronic Obstructive Pulmonary Disease, 2024). Whether doxepin carries a materially different respiratory risk profile in COPD has not been established here and should be discussed with a prescriber for patients with lung disease.

Doxepin has not been directly compared with zolpidem, eszopiclone, or zaleplon in a published head-to-head randomized trial as of this writing. Differences described in this section come from separate trials and label data for each drug, not from a shared study, so any ranking of "better" or "worse" across drugs is an inference rather than a direct finding.

A broader look at the evidence base is worth stating plainly: a systematic review of antidepressants used for insomnia (which includes doxepin) found that the overall quality of evidence for this drug class as sleep treatment is limited, with many trials being small or short in duration (Antidepressants for insomnia in adults, 2018). This does not override doxepin's specific FDA approval, which was based on its own trial program, but it is a useful check against treating doxepin's evidence base as equivalent in size or maturity to the decades of z-drug and benzodiazepine data.

Who is a reasonable candidate, and where clinical judgment is required

People with chronic difficulty staying asleep, rather than falling asleep, are the population the FDA approval targets. Within that group, doxepin is more often discussed for:

• Older adults, because it is not on the list of medications flagged by geriatric prescribing guidelines the way sedative-hypnotics and some GABA-A drugs are, though any older adult starting a new sedating medication should still be monitored for falls, confusion, and interactions with other anticholinergic drugs.
• People with a history of substance use disorder, because doxepin at sleep doses is not a controlled substance, which removes one specific concern (though not all sedation-related concerns) that applies to Schedule IV hypnotics.
• People who have had rebound insomnia after stopping a z-drug, since doxepin's discontinuation profile in its own trials did not show the same rebound pattern.

Cognitive behavioral therapy for insomnia (CBT-I) is widely regarded by sleep medicine guidelines as the preferred first-line treatment for chronic insomnia, with medication reserved for when CBT-I is unavailable, declined, or insufficient alone. This is a guideline-level recommendation from sleep medicine and general internal medicine professional bodies; readers should confirm the current version of that guidance with their prescriber or a sleep medicine reference, since this draft does not carry a verified citation to the specific guideline document.

What is established, what is plausible, and what is not established

Established: Doxepin 3 mg and 6 mg is FDA-approved for sleep-maintenance insomnia in adults, based on the agency's review of the manufacturer's trial data; it is not a controlled substance; the FDA has issued general warnings about next-morning impairment for insomnia drugs as a class, with specific dose changes required for zolpidem.

Plausible but not proven by a shared trial: That doxepin causes meaningfully less rebound insomnia, less sleep-architecture disruption, or less next-morning impairment than zolpidem, eszopiclone, or zaleplon specifically. Each of these claims rests on separate trials of each drug, not a comparative study, so the size of any real-world advantage is uncertain.

Not established here: Doxepin's cardiac safety at sleep doses in people with pre-existing heart disease; its comparative safety in COPD or other respiratory disease relative to z-drugs; and long-term (multi-year) tolerance or dependence patterns beyond the duration of its original approval trials.

When to seek urgent or same-day care instead of adjusting a sleep medication

Chronic insomnia is rarely an emergency, but certain situations need prompt medical attention rather than a medication change: new chest pain, fainting, severe confusion, suicidal thoughts, signs of an allergic reaction, or a suspected overdose (intentional or accidental, especially in combination with alcohol or other sedatives). Anyone experiencing these should seek urgent care or call emergency services rather than waiting for a routine follow-up.

A decision framework for matching an insomnia complaint to an approved mechanism

This framework can help guide initial discussions with your sleep specialist but should not replace direct clinical consultation, and sleep medication dosing and diagnostic assessments must always be individualized.